206 related articles for article (PubMed ID: 35922426)
1. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
Rasche L; Schinke C; Maura F; Bauer MA; Ashby C; Deshpande S; Poos AM; Zangari M; Thanendrarajan S; Davies FE; Walker BA; Barlogie B; Landgren O; Morgan GJ; van Rhee F; Weinhold N
Nat Commun; 2022 Aug; 13(1):4517. PubMed ID: 35922426
[TBL] [Abstract][Full Text] [Related]
2. Accelerated single cell seeding in relapsed multiple myeloma.
Landau HJ; Yellapantula V; Diamond BT; Rustad EH; Maclachlan KH; Gundem G; Medina-Martinez J; Ossa JA; Levine MF; Zhou Y; Kappagantula R; Baez P; Attiyeh M; Makohon-Moore A; Zhang L; Boyle EM; Ashby C; Blaney P; Patel M; Zhang Y; Dogan A; Chung DJ; Giralt S; Lahoud OB; Peled JU; Scordo M; Shah G; Hassoun H; Korde NS; Lesokhin AM; Lu S; Mailankody S; Shah U; Smith E; Hultcrantz ML; Ulaner GA; van Rhee F; Morgan GJ; Landgren O; Papaemmanuil E; Iacobuzio-Donahue C; Maura F
Nat Commun; 2020 Jul; 11(1):3617. PubMed ID: 32680998
[TBL] [Abstract][Full Text] [Related]
3. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.
Waheed S; Mitchell A; Usmani S; Epstein J; Yaccoby S; Nair B; van Hemert R; Angtuaco E; Brown T; Bartel T; McDonald J; Anaissie E; van Rhee F; Crowley J; Barlogie B
Haematologica; 2013 Jan; 98(1):71-8. PubMed ID: 22733020
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma.
Mithraprabhu S; Sirdesai S; Chen M; Khong T; Spencer A
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29937522
[TBL] [Abstract][Full Text] [Related]
5. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.
Melchor L; Brioli A; Wardell CP; Murison A; Potter NE; Kaiser MF; Fryer RA; Johnson DC; Begum DB; Hulkki Wilson S; Vijayaraghavan G; Titley I; Cavo M; Davies FE; Walker BA; Morgan GJ
Leukemia; 2014 Aug; 28(8):1705-15. PubMed ID: 24480973
[TBL] [Abstract][Full Text] [Related]
6. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.
John L; Poos AM; Brobeil A; Schinke C; Huhn S; Prokoph N; Lutz R; Wagner B; Zangari M; Tirier SM; Mallm JP; Schumacher S; Vonficht D; Solé-Boldo L; Quick S; Steiger S; Przybilla MJ; Bauer K; Baumann A; Hemmer S; Rehnitz C; Lückerath C; Sachpekidis C; Mechtersheimer G; Haberkorn U; Dimitrakopoulou-Strauss A; Reichert P; Barlogie B; Müller-Tidow C; Goldschmidt H; Hillengass J; Rasche L; Haas SF; van Rhee F; Rippe K; Raab MS; Sauer S; Weinhold N
Nat Commun; 2023 Aug; 14(1):5011. PubMed ID: 37591845
[TBL] [Abstract][Full Text] [Related]
7. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
[No Abstract] [Full Text] [Related]
8. Evolutionary dynamics of residual disease in human glioblastoma.
Spiteri I; Caravagna G; Cresswell GD; Vatsiou A; Nichol D; Acar A; Ermini L; Chkhaidze K; Werner B; Mair R; Brognaro E; Verhaak RGW; Sanguinetti G; Piccirillo SGM; Watts C; Sottoriva A
Ann Oncol; 2019 Mar; 30(3):456-463. PubMed ID: 30452544
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
Yang WC; Lin SF
Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.
He H; Li Z; Lu J; Qiang W; Jiang S; Xu Y; Fu W; Zhai X; Zhou L; Qian M; Du J
Clin Transl Med; 2022 Mar; 12(3):e757. PubMed ID: 35297204
[TBL] [Abstract][Full Text] [Related]
11. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
[TBL] [Abstract][Full Text] [Related]
12. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.
Merz M; Merz AMA; Wang J; Wei L; Hu Q; Hutson N; Rondeau C; Celotto K; Belal A; Alberico R; Block AW; Mohammadpour H; Wallace PK; Tario J; Luce J; Glenn ST; Singh P; Herr MM; Hahn T; Samur M; Munshi N; Liu S; McCarthy PL; Hillengass J
Nat Commun; 2022 Feb; 13(1):807. PubMed ID: 35145077
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma clonal evolution in homogeneously treated patients.
Corre J; Cleynen A; Robiou du Pont S; Buisson L; Bolli N; Attal M; Munshi N; Avet-Loiseau H
Leukemia; 2018 Dec; 32(12):2636-2647. PubMed ID: 29895955
[TBL] [Abstract][Full Text] [Related]
14. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
[TBL] [Abstract][Full Text] [Related]
15. Multiple Myeloma Guidelines and Their Recent Updates: Implications for Imaging.
Mosebach J; Thierjung H; Schlemmer HP; Delorme S
Rofo; 2019 Nov; 191(11):998-1009. PubMed ID: 31137045
[TBL] [Abstract][Full Text] [Related]
16. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.
Yan Y; Qin X; Liu J; Fan H; Yan W; Liu L; Du C; Yu Z; Xu Y; Hao M; Deng S; Sui W; Lyu R; Liu W; Wang Q; Zou D; Hu L; Wang J; Tai YT; Anderson KC; Zhang L; Cheng T; Zetterberg A; Munshi NC; Qiu L; An G
Blood Adv; 2022 Jan; 6(2):441-451. PubMed ID: 34653241
[TBL] [Abstract][Full Text] [Related]
17. Impact of Clonal Heterogeneity in Multiple Myeloma.
Schinke C; Rasche L; Raab MS; Weinhold N
Hematol Oncol Clin North Am; 2024 Apr; 38(2):461-476. PubMed ID: 38195308
[TBL] [Abstract][Full Text] [Related]
18. Role of FDG PET in the staging of multiple myeloma.
Vicentini JRT; Bredella MA
Skeletal Radiol; 2022 Jan; 51(1):31-41. PubMed ID: 33813607
[No Abstract] [Full Text] [Related]
19. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
[TBL] [Abstract][Full Text] [Related]
20. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
